What's new? Log in Free sign up

Protagonist Therapeutics (PTGX)

Company Profile

Company profile

Ticker

PTGX

Exchange

Website

www.protagonist-inc.com

CEO

Dr. Dinesh V. Patel Ph.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

Former names

Protagonist Inc, Protagonist Therapeutics Inc

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Protagonist Pty Limited ...

IRS number

980505495

PTGX stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$64.60

Low target

$38.00

High target

$80.00

Truist Securities

HC Wainwright & Co.

Latest filings (excl ownership)

View all

Icotrokinra Clinical Study Results Demonstrate its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis

Icotrokinra Clinical Study Results Demonstrate its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

Registration of securities for employees

21 Feb 25

Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Departure of Directors or Certain Officers

Entry into a Material Definitive Agreement

Quarterly report

7 Nov 24

Transcripts

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Deep Track Capital, LP

William D. Waddill

Notice of proposed sale of securities

ARTURO MD MOLINA

Notice of proposed sale of securities

Notice of proposed sale of securities

DINESH V PH D PATEL

DINESH V PH D PATEL

Farallon Capital Partners, L.P.

Financial summary

Financial statements Chart PTGX financial data

Quarter (USD)	Dec 24	Sep 24	Jun 24	Mar 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	97.47 mm	97.47 mm	97.47 mm	97.47 mm	97.47 mm	97.47 mm
Cash burn (monthly)	11.29 mm	7.46 mm	(no burn)	(no burn)	9.73 mm	(no burn)
Cash used (since last report)	41.76 mm	27.58 mm	n/a	n/a	35.98 mm	n/a
Cash remaining	55.71 mm	69.89 mm	n/a	n/a	61.50 mm	n/a
Runway (months of cash)	4.9	9.4	n/a	n/a	6.3	n/a

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

PTGX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	242	241	+0.4%
Opened positions	47	76	-38.2%
Closed positions	46	27	+70.4%
Increased positions	92	77	+19.5%
Reduced positions	74	64	+15.6%

13F shares	Current	Prev Q	Change
Total value	2.36 tn	2.68 tn	-11.7%
Total shares	73.56 mm	71.72 mm	+2.6%
Total puts	217.70 k	113.80 k	+91.3%
Total calls	224.80 k	76.30 k	+194.6%
Total put/call ratio	1.0	1.5	-35.1%

Largest owners	Shares	Value	Change
BlackRock	9.88 mm	$381.55 bn	-3.3%
Farallon Capital Management	5.93 mm	$228.90 bn	+1.2%
Farallon Capital Partners	5.83 mm	$227.92 mm	+4.1%
RTW Investments	5.50 mm	$212.24 bn	+1.3%
Vanguard	4.22 mm	$162.89 bn	+0.1%
STT State Street	3.33 mm	$128.58 bn	+4.6%
Biotechnology Value Fund L P	2.97 mm	$141.45 mm	0.0%
JNJ Johnson & Johnson	2.45 mm	$94.54 bn	0.0%
BVF	1.90 mm	$73.34 bn	+2.7%
Pacer Advisors	1.88 mm	$72.43 bn	+8.2%

Largest transactions	Shares	Bought/sold	Change
Adage Capital Partners GP, L.L.C.	0.00	-1.20 mm	EXIT
Deep Track Capital	1.00 mm	+1.00 mm	NEW
Wellington Management	940.08 k	+910.00 k	+3025.4%
American Century Companies	928.29 k	+353.51 k	+61.5%
TD The Toronto-Dominion Bank	340.97 k	+340.97 k	NEW
Cowen And	0.00	-340.97 k	EXIT
BlackRock	9.88 mm	-339.68 k	-3.3%
JEF Jefferies Financial	1.49 mm	-325.20 k	-17.9%
RJF Raymond James Financial	303.31 k	+303.31 k	NEW
Marshall Wace	19.72 k	-295.66 k	-93.7%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

PTGX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
17 Mar 25	Waddill William D.	Common Stock	Sell	Dispose S	No	Yes	54.25	4,000	217.00 k	13,130
13 Mar 25	Molina Arturo MD	Common Stock	Sell	Dispose S	No	No	55.74	30,514	1.70 mm	83,892
13 Mar 25	Molina Arturo MD	Common Stock	Option exercise	Acquire M	No	No	38.98	2,077	80.96 k	114,406
13 Mar 25	Molina Arturo MD	Common Stock	Option exercise	Acquire M	No	No	23.42	28,437	665.99 k	112,329
13 Mar 25	Molina Arturo MD	Stock Option Common Stock	Option exercise	Dispose M	No	No	38.98	2,077	80.96 k	47,785
13 Mar 25	Molina Arturo MD	Stock Option Common Stock	Option exercise	Dispose M	No	No	23.42	28,437	665.99 k	69,063
12 Mar 25	Asif Ali	Common Stock	Sell	Dispose S	No	No	58.73	24,903	1.46 mm	62,821
12 Mar 25	Asif Ali	Common Stock	Option exercise	Acquire M	No	No	19.19	9,700	186.14 k	87,724
12 Mar 25	Asif Ali	Common Stock	Option exercise	Acquire M	No	No	12.17	15,203	185.02 k	78,024
12 Mar 25	Asif Ali	Stock Option Common Stock	Option exercise	Dispose M	No	No	19.19	9,700	186.14 k	66,800

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

HC Wainwright & Co. Reiterates Buy on Protagonist Therapeutics, Maintains $80 Price Target

HC Wainwright & Co. analyst Douglas Tsao reiterates Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and maintains $80 price target.

Johnson & Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study

Protagonist and Johnson & Johnson report positive Phase 3 data on icotrokinra in adolescent plaque psoriasis, showing high clearance rates and favorable safety.

Johnson & Johnson Presents Icotrokinra Results Showing 75% Of Adolescents With Plaque Psoriasis Achieved Completely Clear Skin And Demonstrate Favorable Safety Profile In A Once Daily Pill

ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults simultaneously 84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16

Wedbush Reiterates Outperform on Protagonist Therapeutics, Maintains $70 Price Target

D-Wave Quantum And IonQ Are Among Top Mid-Cap Stock Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio?

Press releases

From Benzinga Pro

Protagonist Therapeutics Reports Granting of Inducement Award

NEWARK, CA / ACCESS Newswire / April 16, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage biopharmaceutical company pioneering the discovery and development of

Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill

84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16ICONIC-LEAD is the first ever Phase 3 registrational study in

Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025

Past Winners include Waymo, Nvidia, Duolingo, and Novo Nordisk, among others NEWARK, CALIFORNIA / ACCESS Newswire / March 18, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a

Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis

Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.